Analysts Offer Insights on Technology Companies: Coherent Corp (COHR), ServiceNow (NOW) and Vertex (VERX)
Analysts updated ratings for three tech companies: Coherent Corp (COHR) maintained a Buy rating with a $350 target, ServiceNow (NOW) kept a Buy rating with a $175 target, and Vertex (VERX) held a Hold rating. Consensus targets are $401.88 for COHR, $159.93 for NOW, and $16.43 for VERX.
How this was made
The 30-second read
Why it matters
New ratings provide actionable signals for traders, especially for COHR and NOW where targets imply notable upside.
Market read
Analyst upgrades may drive short‑term buying interest in the highlighted stocks.
What to watch
Potential supply‑chain constraints or macro‑economic headwinds could temper upside.
Background
The article aggregates fresh analyst ratings and price targets for three technology companies.
Ticker impact
Analyst Daniel Zhu maintained a Buy rating on Coherent Corp with a $350 price target, up from the $232 close.
likely upward pressure as investors price in the $350 target.
Analyst upgrade with a sizable upside relative to current price.
Piper Sandler analyst Billy Fitzsimmons kept a Buy rating on ServiceNow with a $175 target, above the $145 close.
potential price rise as market absorbs the higher target.
New rating and target provide fresh bullish signal.
BMO Capital analyst Daniel Jester held a Hold rating on Vertex with a $14.50‑$16.43 target range, above the $13.53 close.
minor upward pressure, but limited by Hold stance.
Analyst maintains Hold but provides a higher price range.
Market effects
Analyst upgrades may lift sentiment across the broader technology sector.
U.S. tech stocks could see modest gains in North American markets.
Limited to investors tracking U.S. tech equities.
Counterpoint
Some investors may view the high targets as overly optimistic given recent market volatility.
Key entities
- companyCoherent Corp
Technology firm receiving a Buy rating and $350 target.
- companyServiceNow
Cloud software provider with a Buy rating and $175 target.
- companyVertex Pharmaceuticals
Biotech firm with a Hold rating and modest upside targets.
